Caliber Imaging & Diagnostics Receives $1.4 Million Order for VivaScope(R) Systems From European Distributor MAVIG GmbH

Expects to Deliver Devices in the First Half of 2014

        Print
| Source: Caliber Imaging & Diagnostics, Inc.

BOSTON and ROCHESTER, N.Y., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announces receipt of $1.4 million in orders for VivaScope® systems from its European distributor MAVIG GmbH. These units are scheduled to be shipped in the first half of 2014. MAVIG has been Caliber's exclusive distributor in Europe for the past eight years.

Giuseppe Solomita, Director International Sales of MAVIG, said, "This order for VivaScope systems further cements our long and solid relationship with Caliber I.D. As evidenced by the magnitude of this order, a growing number of physicians, hospitals and clinics throughout Europe are recognizing the benefits of using VivaScope. We believe Caliber's noninvasive point-of-care platform imaging technology represents an important advancement in diagnostics and medical research, and we are pleased to have a long relationship with the Company."  

L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "The European healthcare market represents a vibrant arena in which to highlight the power of VivaScope. As we continue to expand our global footprint, Europe will remain a key focus of our distribution efforts, and MAVIG has proven to be the ideal partner in this endeavor. We look forward to the broadened use of our VivaScope system in the European market, and to building on the approximately 200 VivaScope units already sold to MAVIG."

Founded in 1921, MAVIG GmbH is a globally successful company with an outstanding reputation in x-ray protection, system solutions and mounting technology for medical equipment.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope significantly improves outcomes and reduces costs, allowing physicians to quickly detect cancerous lesions that appear benign. VivaScope dramatically reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the cosmetics industry. For more information about Caliber I.D. and its products, please visit www.caliberid.com.

VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.

Company Contact:
Richard Pulsifer
Chief Financial Officer
(617) 348-9821

Investor Relations Contact:
LHA
Kim Sutton Golodetz
(212) 838-3777


Public Relations Contacts:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
(212) 825-3210